Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.52 |
| ▸ | THRB | P10828 | 5/20 | 0.48 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.40 |
| ▸ | ABL2 | P42684 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868066 | 0.89 | TGFBR1 (0.41) | TGFBR1MAPK14THRBTGFBR2 | |
| SCHEMBL413055 | 0.83 | TGFBR1 (0.44) | TGFBR1MAPK14THRB | |
| SCHEMBL5236790 | 0.82 | TGFBR1 (0.45) | TGFBR1TGFBR2 | |
| SCHEMBL4872219 | 0.82 | TGFBR1 (0.51) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL4874504 | 0.81 | TGFBR1 (0.57) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL4869104 | 0.78 | TGFBR1 (0.47) | TGFBR1MAPK14THRBTGFBR2CSNK1A1 | |
| SCHEMBL413214 | 0.77 | TGFBR1 (0.50) | TGFBR1MAPK14THRB | |
| SCHEMBL4868582 | 0.76 | MEN1 (0.46) | TGFBR1MAPK14THRB | |
| SCHEMBL5233037 | 0.74 | TGFBR1 (0.45) | TGFBR1MAPK14THRBGRM4 | |
| SCHEMBL412610 | 0.73 | TGFBR1 (0.46) | TGFBR1MAPK14THRBTGFBR2CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | claimed |
| EP-1543001-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |